What is Epsilogen?
Epsilogen is a pioneering biopharmaceutical firm dedicated to the engineering of pan-isotype antibody therapeutics designed to revolutionize cancer treatment. The company distinguishes itself through its focus on immunoglobulin IgE, IgA, and IgG-based therapies, which aim to harness the immune system's full potential against malignant cells. Its lead candidate, MOv18 IgE, represents a significant milestone as the first therapeutic IgE antibody to enter clinical trials, specifically targeting folate receptors in patients suffering from platinum-resistant ovarian cancer.
By strategically matching antibody isotypes to specific cancer profiles, Epsilogen is creating a new paradigm in precision medicine. The company's ability to optimize immune responses positions it at the forefront of oncology research, offering hope for improved patient outcomes in areas where traditional treatments have historically faced limitations.
How much funding has Epsilogen raised?
Epsilogen has raised a total of $67.8M across 3 funding rounds:
Series A
$6.3M
Other Financing Round
$3.9M
Series B
$57.6M
Series A (2017): $6.3M with participation from Epidarex Capital, UCL Technology Fund, and Alsa Holdings
Other Financing Round (2020): $3.9M led by Epidarex Capital, UCL Technology Fund, and Alsa Holdings
Series B (2024): $57.6M supported by Caribou Property Management, Epidarex Capital, Schroders Capital, ALSA Ventures, British Patient Capital, 3B Future Health Fund, and Novartis Venture Fund
Key Investors in Epsilogen
Epidarex Capital
A transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs, leveraging deep scientific networks to foster innovation.
UCL Technology Fund
An investment vehicle dedicated to the commercialization of research opportunities from University College London, providing capital and expertise to scale life science ventures.
Novartis Venture Fund
A life science-focused venture fund that invests in innovative biotechnology and biopharmaceutical therapeutics to address significant unmet patient needs.
What's next for Epsilogen?
With the successful closure of this major strategic investment, Epsilogen is well-positioned to accelerate its clinical development programs and expand its research capabilities. The influx of capital will likely be directed toward advancing its lead therapeutic candidates through critical trial phases and potentially broadening its pipeline to address a wider array of solid tumors. As the company transitions into this next phase of growth, the focus will remain on validating its pan-isotype platform and establishing key partnerships within the global biopharmaceutical landscape to bring these novel therapies to market.
The strategic backing from a diverse group of investors provides not only the necessary financial runway but also the industry expertise required to navigate the complexities of late-stage clinical development and regulatory approval, ensuring that Epsilogen remains a dominant force in the future of cancer immunotherapy.
